|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0026336,
umls-concept:C0026339,
umls-concept:C0205198,
umls-concept:C0205314,
umls-concept:C0497327,
umls-concept:C0599946,
umls-concept:C0679466,
umls-concept:C0679622,
umls-concept:C0815279,
umls-concept:C1515655,
umls-concept:C1533691,
umls-concept:C2000951
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-7-31
|
|
pubmed:abstractText |
To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0360-4012
|
|
pubmed:author |
pubmed-author:ChoiJin-HoJH,
pubmed-author:KimHee JinHJ,
pubmed-author:KimHye-SunHS,
pubmed-author:KimSeonghanS,
pubmed-author:LeeGeon HoGH,
pubmed-author:LeeHyung GunHG,
pubmed-author:LeeKwan-SunKS,
pubmed-author:ParkCheol HyoungCH,
pubmed-author:ParkSoo-HyunSH,
pubmed-author:ShinKi YoungKY,
pubmed-author:SuhYoo-HunYH,
pubmed-author:WonBeom YoungBY
|
|
pubmed:copyrightInfo |
Copyright 2007 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2500-11
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17600377-Amyloid beta-Peptides,
pubmed-meshheading:17600377-Animals,
pubmed-meshheading:17600377-Apoptosis,
pubmed-meshheading:17600377-Blotting, Western,
pubmed-meshheading:17600377-Caspase 3,
pubmed-meshheading:17600377-Cognition,
pubmed-meshheading:17600377-Coumaric Acids,
pubmed-meshheading:17600377-Cytochromes c,
pubmed-meshheading:17600377-Dementia,
pubmed-meshheading:17600377-Disease Models, Animal,
pubmed-meshheading:17600377-Enzyme Activation,
pubmed-meshheading:17600377-In Situ Nick-End Labeling,
pubmed-meshheading:17600377-Muscarinic Antagonists,
pubmed-meshheading:17600377-Neuroprotective Agents,
pubmed-meshheading:17600377-Pyrones,
pubmed-meshheading:17600377-Rats,
pubmed-meshheading:17600377-Rats, Wistar,
pubmed-meshheading:17600377-Reactive Oxygen Species,
pubmed-meshheading:17600377-Scopolamine Hydrobromide
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.
|
|
pubmed:affiliation |
Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, MRC, Seoul National University, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
